Previously, Shanghai medicine had issued a performance report for 2022. During the reporting period, the company achieved operating income of $231.981 million, an increase of 7.49 per cent over the same period; net profits belonging to shareholders of listed companies of $5617 million, an increase of 10.28 per cent over the same period.

This good performance, of course, cannot be overtaken by the top management of the company, and the Managing Director of Shanghai Medicine has attracted the attention of the operator, who has tried to shed light.

According to public information, the birth of the left sensitizer in May 1961 is now 62 years old, and this age is still on the verge of honour. It is known that the left sensitize graduate from the Pharmacological specialization of the University of Sichuan (formerly the University of Chinese Medical Sciences), followed by a master’s degree in management in the School of Management. While it is not known about the exact time of graduation of the master’s degree, it is quite difficult to obtain such a degree.

The work of the left sensitizers has been rich, having served as Vice-President, Executive Director, Ernst and Young, Deputy Managing Director of the China-West Pharmaceutical Group, Deputy General Manager of the Thirty-9 Business Group, Director-General, Board Manager of Thirty-9 Trading and Ninestar Printing Company Ltd., Vice-Chair of the South Pharmaceutical Plant, Minister of Marketing, Director of the Liquids Unit, Director of the Cell, Pharmacist, etc., of the South Hospital of the First Medical University of the State, whose capacity is not low.

Since June 2013, all of them have served as executive directors and Managing Directors of Shanghai Medicine, and have been in office for almost a decade now, with deep qualifications.

Anthropogenic information shows that left sensitizers earned $6.064 million in 2022 and that the marketed company A was absolutely low, but that, even so, the left sensitized remuneration was still not carried out and the deputy Managing Director, Lee Yong, received $652.12 million in loyalty.

It is a matter of concern that, in April 2021, the Ministry of Finance, Finance and Political Affairs penalized 19 pharmaceutical enterprises and placed on the list of four controlled companies under the flag of the Hellenic Medical Group.

Specifically, the Shanghai Friends Joint Medicines Company, Inc., received an increase of $43.36 million in travel in 2018. In addition, the accompanying portion of the cost of research and advisory services charged by the Department of Friends in the context of operating extension costs in 2018 is not accurate, covering a total amount of $6,612,000.

SCO is involved in an amount of $565.72 million owing to the lack of information on the back-to-back share of the royalties for academic activities in 2018.

Shanthi Pharmaceuticals Ltd. charged part-time operator costs, office rental costs in 2018, certified as refuelling invoices, transport invoices, amounting to $113.73 million.

The back-to-back information for the conference fees of Shanghai New Pharmaceuticals Ltd. for the period 2018 was not available, amounting to $8.439 million.